Heart Failure in T2DM: Ready for Prime Time?
Nov 24, 2020
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Louise Brown, PharmD Candidate, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Although not the most prevalent comorbid condition in patients with T2DM, heart failure was the most fatal in a 17-year long nationwide real-life cohort study.
The risk of developing heart failure (HF) in patients with T2DM is double for men and triple for women compared to patients without T2DM. In 2008, the FDA introduced new guidelines that required cardiovascular (CV) safety studies for T2DM medications. Major atherosclerotic coronary events were the primary focus of these studies. It is noteworthy that structural heart disease, including HF, was not included as a primary outcome in these guidelines. Although still not an original primary endpoint, reducing HF hospitalizations is now recognized as an essential safety outcome in diabetes trials....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.